← Back to Search

Other

ZN-c3 for Solid Tumors

Phase 1
Recruiting
Research Sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through completion, average of 1 year
Awards & highlights

Study Summary

This trial is testing a new drug, ZN-c3, to see if it is safe and effective when used alone or with other drugs.

Eligible Conditions
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through completion, average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through completion, average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Dose Escalation
Dose Expansion
Secondary outcome measures
Dose Escalation, Food Effect cohort & Dose Expansion
Dose Escalation, Food Effect cohort and Dose Expansion
Food Effect Cohort

Trial Design

3Treatment groups
Experimental Treatment
Group I: Single Agent Food Effect CohortExperimental Treatment1 Intervention
Subjects with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available. This cohort will give subjects the option to continue treatment after PK assessments are completed.
Group II: Single Agent Dose ExpansionExperimental Treatment1 Intervention
Subjects with histologically confirmed recurrent or persistent USC who have had treatment with at least 1 prior platinum-based chemotherapy regimen for management of advanced or metastatic USC and subjects with locally advanced or metastatic malignancy with one or more relevant biomarkers related to DNA damage pathways.
Group III: Single Agent Dose EscalationExperimental Treatment1 Intervention
Subjects with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available.

Find a Location

Who is running the clinical trial?

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncLead Sponsor
7 Previous Clinical Trials
698 Total Patients Enrolled
K-Group BetaLead Sponsor
5 Previous Clinical Trials
582 Total Patients Enrolled
Philippe Pultar, MDStudy DirectorK-Group Beta, a Zentalis Company
2 Previous Clinical Trials
484 Total Patients Enrolled
~27 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top